The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of docetaxel with or without risedronate in patients with bone metastases from castration-resistant prostate cancer (CRPC): The Netherlands Prostate Study (NePro).
H. J. Meulenbeld
No relevant relationships to disclose
E. D. van Werkhoven
No relevant relationships to disclose
J. L. L. M. Coenen
No relevant relationships to disclose
G. Creemers
No relevant relationships to disclose
O. J. L. Loosveld
No relevant relationships to disclose
P. C. De Jong
No relevant relationships to disclose
A. J. Ten Tije
No relevant relationships to disclose
S. D. Fossa
No relevant relationships to disclose
M. Polee
No relevant relationships to disclose
W. R. Gerritsen
No relevant relationships to disclose
O. Dalesio
No relevant relationships to disclose
R. De Wit
Honoraria - Sanofi (I)
Research Funding - Sanofi